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Although cancer cells are not generally controlled by
normal regulatory mechanisms, tumor growth is
highly dependent on the supply of oxygen, nutrients,
and host-derived regulators. It is now established that
tumor vasculature is not necessarily derived from en-
dothelial cell sprouting; instead, cancer tissue can
acquire its vasculature by co-option of pre-existing
vessels, intussusceptive microvascular growth, post-
natal vasculogenesis, glomeruloid angiogenesis, or
vasculogenic mimicry. The best-known molecular
pathway driving tumor vascularization is the hypox-
ia-adaptation mechanism. However, a broad and di-
verse spectrum of genetic aberrations is associated
with the development of the “angiogenic phenotype.”
Based on this knowledge, novel forms of antivascular
modalities have been developed in the past decade.
When applying these targeted therapies , the stage
of tumor progression, the type of vascularization of
the given cancer tissue, and the molecular machin-
ery behind the vascularization process all need to
be considered. A further challenge is finding the
most appropriate combinations of antivascular
therapies and standard radio- and chemotherapies.
This review intends to integrate our recent knowl-
edge in this field into a rational strategy that could
be the basis for developing effective clinical modal-
ities using antivascular therapy for cancer. (Am J
Pathol 2007, 170:1–15; DOI: 10.2353/ajpath.2007.060302)
Until recently, vascularization of malignant tumors was
considered the exclusive result of directed capillary
ingrowth (endothelial sprouting). However, recent ad-
vances have been made in identifying the processes
involved in angiogenesis and vascular remodeling.
Consequently, the simplistic model of an invading cap-
illary sprout has been deemed insufficient to describe
the entire spectrum of morphogenic and molecular
events required to form a neovascular network. Before
discussing the different ways a tumor is vascularized,
we should emphasize that these mechanisms are not
mutually exclusive; in fact, in most cases they are
interlinked, participating concurrently in physiological
as well as in pathological angiogenesis. Although the
various types of cancer vascularization share some
molecular features and may be controlled in part by
similar sets of regulatory factors, a considerable vari-
ety of differences also exists. Although the molecular
regulation of endothelial sprouting has been exten-
sively studied and reviewed in the literature, the mor-
phogenic and molecular events associated with alter-
native cancer vascularization mechanisms are less
understood. Therefore, this review focuses on the
pathogenesis of the different forms of “nonsprouting
angiogenesis” and, more specifically, on the possibil-
ities and the potential use of novel antiangiogenic and
vascular targeting strategies against alternative tumor
vascularization mechanisms.
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Vascularization Mechanisms in Cancer
Endothelial Sprouting
The best-known mechanism by which tumors promote
their own vascularization is inducing new capillary buds
from pre-existing host tissue capillaries. The first descrip-
tion of this process dates back to the 1970s, when Aus-
prunk and Folkman1 suggested the following sequence
for tumor-induced capillary sprouting (Figure 1, Alt. 1). 1)
The basement membrane is locally degraded on the side
of the dilated peritumoral postcapillary venule situated
closest to the angiogenic stimulus, interendothelial con-
tacts are weakened, and endothelial cells (ECs) emigrate
into the connective tissue, toward the angiogenic stimuli.
2) There is formation of a solid cord by ECs succeeding
one another in a bipolar fashion. 3) Lumen formation
occurs by cell-body curving of a single EC or by partic-
ipation of more ECs in parallel with the synthesis of the
new basement membrane and the recruitment of peri-
cytes/mural cells. The main disadvantages of this model
are its inability to identify the nature and origin of the
stimulus necessary for lumen formation and the assump-
tion that dedifferentiation and redifferentiation take place
during the same process, manifest in the loss and regain-
ing of luminal-basal EC polarity. Furthermore, although it
has been well established that the stimulus necessary for
lumen formation comes from the developing basement
membrane, according to this model, basement mem-
brane deposition occurs after lumen formation. In the
early 1990s, a different sprouting model was described2
(Figure 1, Alt. 2). This model suggests a three-stage
sequence to explain ultrastructural changes during tu-
mor-induced endothelial sprouting. 1) There is structural
alteration of the basement membrane characterized by
the loss of electron density (gel-sol transition) over the
entire circumference of the dilated “mother vessel” (al-
though basement membrane components such as lami-
nin and collagen IV can still be detected by immunohis-
tochemistry). Partial and regulated degradation of the
altered basement membrane occur only at places where
EC processes (connected by intercellular junctions) are
projecting into the connecting tissue. 2) Further migration
of ECs, which are arranged in parallel, maintaining their
basal-luminal polarity and forming a slit-like lumen, takes
place continuously with the lumen of the mother vessel
and sealed by intact interendothelial junctions. Basement
membrane of low electron density is deposited continu-
ously by the polarized ECs while only the very tip of the
growing capillary bud is free of basement membrane
material. 3) Proliferating pericytes of the mother vessel
migrate along the basement membrane of the capillary
bud, resulting in complete pericyte coverage of the new
vessel. In parallel, the appearance of electron-dense
basement membrane around the maturing capillary buds
(sol-gel transition) can be observed. According to the
above model, no stimulus is necessary for the induction
of lumen formation, because ECs do not lose their polarity
during the process.
The molecular background of capillary sprouting has
been extensively studied and reviewed in the literature.3
During the process, vessels initially dilate and become
leaky in response to vascular permeability factor/vascular
endothelial growth factor (VPF/VEGF).4 This is mediated
by the up-regulation of nitric oxide, the development of
fenestrations and vesiculo-vacuolar organelles, and by
the redistribution of CD31/PECAM-1 and vascular endo-
thelial (VE)-cadherin. The so-called gel-sol transition of
the basement membrane, probably mediated by matrix
metalloproteases (MMPs), gelatinases, and the urokinase
plasminogen activator system, could be partly responsi-
ble for the initiation of EC proliferation and migration.
Ang-2 (Angiopoetin-2, a mediator of Tie-2 signaling) is
involved in the detachment of pericytes and loosening of
the matrix. A vast number of molecules stimulate endo-
thelial proliferation and migration, including transforming
growth factor (TGF)-1, tumor necrosis factor (TNF)-,
members of the chemokine system and the VEGF, fibro-
blast growth factor, and platelet-derived growth factor
(PDGF) families.3 It could be argued that integrins repre-
sent the most important adhesion receptors in migrating
ECs.5 A wide variety of integrins have been shown to be
expressed during sprouting, including 11, 21, 31,
51, v5, and v3. Perhaps the most important among
them is v3, which mediates the migration of ECs in the
fibrin-containing cancer stroma and maintains the sol
state of the basement membrane because of its ability to
bind to MMP-2. During maturation of nascent vessels,
PDGF-BB recruits pericytes and smooth muscle cells,
Figure 1. Endothelial sprouting. Schematic representation of the EC sprout-
ing models suggested by Ausprunk and Folkman (Alt. 11) and by Paku and
Paweletz (Alt. 22). Red cells represent endothelial cells; brown cells are
pericytes. Yellow cells are mural cells of other origin (fibroblasts or bone
marrow-derived cells). See Vascularization Mechanisms in Cancer for details.
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whereas TGF-1 and Ang-1/Tie-2 stabilize the interaction
between endothelial and mural cells.3 All in all, sprouting
is controlled by a tightly regulated balance of proangio-
genic factors and inhibitors: an angiogenic cytokine pro-
motes EC proliferation, migration, or lumen formation,
whereas an inhibitor interferes with these steps and mod-
ulates the proliferation or migration activity of ECs. How-
ever, individual tumor types use various combinations of
proangiogenic and inhibitory cytokines.3
Vessel Co-Option
When tumors arise in or metastasize to a pre-existing,
usually well-vascularized, tissue, their growth not only
depends on expansion, like a balloon, more typical of
slow-growing benign tumors, but also on the invasion of
host tissue, allowing the cancer cells close contact with
the surface of blood vessels. Therefore, malignant cells
may initially associate with and grow preferentially along
pre-existing microvessels. Until recently, however, no
studies have focused on the role played by the host
vasculature in the process of tumor vascularization. Al-
though in 1987 Thompson6 had already proposed that
tumors acquire their vasculature by incorporation of host
tissue capillaries, the first study suggesting the existence
of vessel co-option was not published until 1999 by Ho-
lash et al.7 In their model, Holash and colleagues found
that co-option is limited to the initial phases of tumorigen-
esis.7 However, additional morphological evidence in hu-
man malignancies suggests that co-option of pre-existing
blood vessels might persist during the entire period of
primary or metastatic tumor growth. In cutaneous mela-
noma, we found that during tumor growth, there are no
signs of directed vessel ingrowth; instead, these tumors
appear to grow by co-opting the massive vascular plexus
present in the peritumoral connective tissue.8 In non-
small cell lung cancer, a putatively nonangiogenic growth
pattern was observed.9 In this “alveolar type” of growth,
cancer cells filled the alveoli, entrapping but not destroy-
ing the co-opted alveolar capillaries. In liver metastases
of human colorectal carcinomas, different growth pat-
terns (replacement, pushing, and desmoplastic) were
observed, depending on the degree of differentiation. In
replacement growth type, the architecture of the liver was
preserved, and the ECs of sinusoids showed low mitotic
activity. However, pushing and desmoplastic tumor types
destroyed the liver architecture.10 According to our pre-
vious results in experimental hepatic metastases, during
growth of sinusoidal-type metastases, invading cancer
cells advance between the basement membrane and the
endothelial lining of the sinusoids and evoke proliferation
of ECs. This process resulted in the development of large
tortuous vessels without basement membrane inside the
tumor nodules. Conversely, sprouting-type angiogenesis
was observed in portal-type metastases. The replace-
ment growth pattern corresponded to sinusoidal-type
metastases of undifferentiated tumors, whereas desmo-
plastic tumors showed similarities to portal-type metasta-
ses.11 In the pushing-type growth pattern, we recently
described a mechanism for the development of blood
supply and supportive connective tissue12 (Figure 2).
This process includes the proliferation of smooth muscle
actin-positive stellate, but not endothelial, cells on the
surface of the tumor spheroid accompanied by capillar-
ization of the sinusoids in this region. Because of the
pressure of the tumor and the proliferating stellate cells,
the hepatocytes disappear from the closest vicinity of the
tumor, leading to the fusion of the sinusoids and the
appearance of vascular lakes at the surface of the tumor.
Together with the collagen-producing cells, these vascu-
lar lakes are incorporated into the tumor, resulting in the
development of vessel-containing connective tissue col-
umns that traverse the tumor. These columns represent
the main structural and functional unit, providing blood
supply for the inner part of the growing metastasis. Thus,
the presence of the above mechanisms further supports
earlier observations that vascularization of metastases in
the liver is a heterogeneous process, depending on the
degree of tumor differentiation or localization of the me-
tastases within the liver.13
Although sprouting capillaries are more vulnerable to
apoptosis than their quiescent counterparts,14 mainte-
nance of incorporated mature microvessels depends on
the survival of ECs as well. The continued survival of
co-opted ECs is intimately tied to their local microenvi-
ronment and, in particular, to the presence of pericytes,
survival-promoting cytokines, and extracellular matrix
proteins. Thus, the molecular repertoire that ECs may use
to survive during vessel co-option is diverse and may
vary for a given tumor type or host environment. The
major players that control this process are angiopoetins
and VEGF.7 Based on the model of vessel co-option
described by Holash et al7 and in other recent studies,15
Ang-1 activates Tie-2 and induces subsequent signal
transduction pathways favoring EC survival, endothelial
quiescence, and tumor-vessel maintenance. Conversely,
Ang-2 is thought to act as a nonsignaling Tie-2 ligand that
binds to endothelial Tie-2 and thereby negatively inter-
feres with agonistic Ang-1/Tie-2 signals. In co-opted
blood vessels, the up-regulation of Ang-2 disrupts the
interaction between Tie-2 and Ang-1, which in turn
causes the destabilization of capillary walls (ie, the de-
tachment of pericytes from the endothelial tube).16 Once
ECs are separated from pericytes, they become particu-
larly vulnerable. In the presence of VEGF, EC survival and
new vessel growth are promoted; however, the lack of
stimulatory factors results in the regression of destabi-
lized vessels.17
VEGF was first described as a survival factor for retinal
ECs and has now been shown to promote survival in
different EC models. This antiapoptotic and survival func-
tion of VEGF seems to depend on an interaction between
vascular endothelial growth factor receptor (VEGFR)-2,
-catenin, and VE-cadherin.18 However, targeting of
VEGF has been shown to result in apoptosis only in newly
formed tumor vessels and in the developing vasculature
of the neonatal mouse but not that of adult mice or of
quiescent tumor vascular networks.17 In summary, al-
though cytokines responsible for EC survival could be the
key molecules, their precise role in initiation and mainte-
nance of vessel co-option still requires investigation.
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Intussusceptive Microvascular Growth (IMG)
IMG refers to vessel network formation by insertion of
connective tissue columns, called tissue pillars, into the
vessel lumen and to subsequent growth of these pillars,
resulting in partitioning of the vessel lumen (Figure 3).
This type of angiogenesis, which has been observed in a
wide variety of normal and malignant tissues, is faster
and more economical than sprouting, occurs within hours
or even minutes and does not primarily depend on EC
proliferation, basement membrane degradation, and in-
vasion of the connective tissue.19 However, in contrast to
sprouting, IMG can work only on existing vessel net-
works. The most important feature of IMG, therefore,
seems to be its ability to increase the complexity and
density of the tumor microvessel network already built by
sprouting, independent of EC proliferation. In addition,
IMG can provide more surface area for further sprouting.
Its molecular regulation, however, is poorly understood
since IMG was first described only a few years ago.
Nevertheless, the role of some players is gradually be-
coming clearer. We know that local stimuli, such as intra-
vascular shear stress, might induce a cascade of phys-
iological or pathological reactions in ECs, and new
capillary development by tissue pillar formation could be
one of them.20 Furthermore, intussusception is certainly
synchronized by several cytokines. Major candidates are
those capable of mediating information between ECs or
from ECs to mural cells, such as PDGF-BB, angiopoi-
Figure 2. Examples for vessel co-option. A–D: Pushing-type angiogenesis in liver metastases of colorectal cancer. A: Cross-section of a compressed invagination.
SMA-expressing cells (blue fluorescence) facing the tumor tissue, hepatocytes are crowded in the middle of the invagination (pan-cytokeratin, green
fluorescence). Continuous CD31 staining (red fluorescence), representing fused sinusoids (arrows), is visible in contact with the SMA-positive cells. Note the
paucity of sinusoids between the hepatocytes. B: Laminin (blue fluorescence) co-localizes with 6 integrin within the columns. The column tightly packed with
SMA-positive cells (red fluorescence). C: 6 integrin (green fluorescence) is present at the periphery of the column and around the central vessel. D: Schematic
representation of the development of vasculature in pushing-type liver metastases. For better visibility of the vessels, hepatocytes are depicted only in the upper
part of the drawings. At the early stage of the tumor development, the tumor faces normal liver architecture. As the compression of the tumor grows, the
hepatocytes “step back,” and fusion of the sinusoids takes place. The fused vessel, together with the newly synthesized connective tissue, is incorporated into the
tumor. The pressure of the tumor results in the separation of the vessel from the liver parenchyma. The vessel in the direction of the axis of the column remains
connected to the sinusoidal system of the liver. Column formation is finished by the back-to-back fusion of the basement membranes of the tumor bulges. Green,
tumor; brown, hepatocytes; red, sinusoids and central vessel.
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etins, and their Tie receptors, TGF-, monocyte chemo-
tactic protein-1, and ephrins and Eph-B receptors.19
After the initial stage of immature capillary network
formation by sprouting, additional vascular growth and
development of complex vascular beds, including their
continuous remodeling and adaptation, may occur by
intussusception in cancers. The absence of intense EC
proliferation in IMG implies that neovascularization by this
mechanism would be resistant to angiosuppressive treat-
ment in itself.
Glomeruloid Angiogenesis
Glomeruloid bodies (GBs) are best known in high-grade
glial malignancies, where they are one of the diagnostic
histopathological features of glioblastoma multiforme.
However, these complex vascular aggregates have also
been described in a wide variety of other malignancies.21
They are composed of several closely associated mi-
crovessels surrounded by a variably thickened basement
membrane within which a limited number of pericytes are
embedded. In recent studies, the presence of GBs was
associated with markers of aggressive tumor behavior
and significantly reduced survival in cancer patients.22 In
the first animal model,23 GBs developed in mother ves-
sels from recruitment and proliferation of ECs and peri-
cytes (in the absence of tumor cells), and VEGF was
essential for their induction and maintenance. In contrast
to this model and based on our previous results in the first
experimental tumor model of glomeruloid angiogene-
sis,24 we believe that GB formation starts immediately
after tumor cell extravasation, much earlier than necrosis
appears within the metastases. We found that the prolif-
erating and migrating tumor cells are able to pull the
capillaries and the adjacent capillary branching points
into the tumor cell nests. This process leads to the ap-
pearance of simple coiled vascular structures that later
develop into GBs with multiple narrowed afferent and
efferent capillaries (Figure 4). Despite the absence of
sprouting angiogenesis, necrosis was scarce in these
lesions, suggesting that the blood supply from the pre-
existent vascular bed is sufficient to provide the tumor
cells with oxygen and nutrients. This type of GB formation
cannot be termed as true angiogenesis; it rather repre-
sents a remodeling of the existing vasculature of the host
tissue. Whether GBs represent an accelerated form of
angiogenesis or a dysfunctional, possibly abortive, form
remains an open question. However, it cannot be ex-
cluded that “active” and “passive” types of glomeruloid
angiogenesis can operate concurrently in various cancer
types.
Postnatal Vasculogenesis: The Role of
Endothelial Progenitor Cells
Vasculogenesis (defined as the in situ differentiation of
vascular ECs from primitive precursor cells) has long
been thought to occur only in the early phases of vascular
development. Recent studies, however, have demon-
strated that circulating bone marrow-derived endothelial
progenitor cells (EPCs) home to sites of physiological
and pathological neovascularization and differentiate into
ECs (Figure 5). EPCs may be mobilized by tumor tissue-
derived cytokines from the bone marrow by a mechanism
recently described by Asahara et al.25 Best character-
ized among these cytokines is VEGF. During tumor pro-
gression, the level of circulating VEGF has been shown to
rise, and this level was found to correlate with the number
of EPCs in the circulation. Furthermore, PDGF-CC pro-
moted vascularization in part by stimulating outgrowth of
EPCs. In contrast, Ang-1 was shown to reduce EPC mo-
bilization from bone marrow (reviewed in Ref. 26).
After homing, ie, after adhesion and insertion of EPCs
into the monolayer of surrounding mature vascular ECs,
additional local stimuli may promote the activation of local
endothelium to express adhesion molecules to recruit
EPCs. This process may be completed by mechanisms
not yet elucidated. In addition to the physical contribution
of EPCs to newly formed microvessels, the angiogenic
cytokine release of EPCs may be a supportive mecha-
nism to improve neovascularization as well.27 It is also
important to note that Lyden et al recently identified
VEGFR-1 hematopoietic progenitor cells that multiply
in the bone marrow, mobilize to the peripheral blood
along with VEGFR-2 EPCs, and incorporate into peri-
capillary connective tissue, thus stabilizing tumor vas-
culature.28 More interestingly, these cells seem to
home in before the tumor cells arrive, promoting met-
astatic growth by forming niches where cancer cells
can locate and proliferate.29
Although EPCs obviously participate in the vascular-
ization process of malignant tumors, it is still unclear
whether they are essential for these processes or what
the relative contribution of EPCs is compared with that of
in situ proliferating ECs. Moreover, it has yet to be deter-
mined whether EPCs can be targeted to treat certain
types of malignancies, or alternatively—as they are en-
dowed with the capacity to home to the tumor vascula-
ture—can be used to deliver toxins or vascular-targeting
agents.
Vasculogenic Mimicry
“Vasculogenic mimicry” is defined by the unique ability of
aggressive melanoma cells to express an EC phenotype
Figure 3. Intussusceptive microvascular growth. Schematic representation of
intussusceptive microvessel growth. The first step of the process is the
development of the transluminal endothelial bridge. This is followed by the
reorganization of the endothelial lining, a process that is largely unknown.
The division of the vessel is completed by the development of a connective
tissue pillar through the vessel lumen. Red cells are endothelial cells; brown
cells are pericytes. Gray, basement membrane.
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and to form vessel-like networks in three-dimensional
culture, “mimicking” the pattern of embryonic vascular
networks and recapitulating the patterned networks seen
in patients’ aggressive tumors correlating with a poor
prognosis.30 Comparative global gene analyses of ag-
gressive and poorly aggressive human cutaneous and
uveal melanoma cell lines unexpectedly revealed the
ability of aggressive tumor cells to express genes (and
proteins) associated with multiple cellular phenotypes
and their respective precursor stem cells, including en-
dothelial, epithelial, pericyte, fibroblast, and several other
cell types.31–33 These new and intriguing findings sup-
port the premise that aggressive melanoma cells acquire
a multipotent, plastic phenotypea concept that chal-
lenges our current thinking on how to target tumor cells
that can possibly masquerade as other cell types, par-
ticularly with embryonic stem cell-like properties. The
etiology of the melanoma vasculogenic phenotype re-
mains unclear; however, it seems to involve dysregulation
of the lineage-specific phenotype and the concomitant
transdifferentiation of aggressive cancer cells into other
cell types—such as endothelial-like cells. Vasculogenic
Figure 4. Glomeruloid angiogenesis. A: Experimental brain metastases stained for laminin (green fluorescence) and CD31 (blue fluorescence), 28 days following
intracarotid inoculation of the A2058 human melanoma cell line. Glomeruloid bodies are connected to each other by a capillary that is very small in diameter
(arrows). The outlines of the metastases are clearly visible because of the strong laminin positivity of the tumor cells (arrowheads). B: Schematic representation
of glomeruloid body formation. Following extravasation, the tumor cells (green) adhere firmly to the abluminal surface of the capillary basement membrane
(gray). In the first step, because of the contractile force of the tumor cell a loop develops on the capillary. Proliferating tumor cells pull the capillary inward,
resulting in the development of further loops and reduction of the diameter of the capillary segment lying outside the glomeruloid body. The last drawing shows
the cross-section of a fully developed glomeruloid body built by ECs (red), pericytes (brown), and tumor cells (green). Extreme large cytoplasmic projections of
the tumor cells adhere to different segments of the capillary.
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mimicry has been confirmed in breast, prostate, ovarian,
chorio-, and lung carcinomas; synovial-, rhabdomyo-,
and Ewing sarcomas; and phaeochromocytoma.34 Ex-
pression profiling studies revealed that the most signifi-
cantly up-regulated genes by aggressive melanoma cells
include those that are involved in angiogenesis and vas-
culogenesis, such as the genes encoding VE-cadherin,
erythropoietin-producing hepatocellular carcinoma-A2
(EphA2), MMPs, and laminin 52 chain (LAMC2). These
molecules, with their binding partners, are a few of the
factors required for the formation and maintenance of
blood vessels and also for vasculogenic mimicry in mel-
anomas. Perhaps equally significant is the down-regula-
tion of the gene MART-1 (melanoma antigen recognized
by T cell 1, also called Melan-A), a classic marker for
melanocytes and melanoma, by aggressive melanoma
cells. The concept of vasculogenic mimicry was devel-
oped further to include the existence of a fluid-conduct-
ing, laminin-containing extracellular matrix meshwork,
providing a site for nutritional exchange for aggressive
tumors, and therefore possibly preventing necrosis (Fig-
ure 6).34,35 Functional studies revealed the close associ-
ation of tumor-cell-lined networks with angiogenic mouse
vessels at the human-mouse interface and the coopera-
tion between the two systems.36,37 The molecular dissec-
tion of the physiological mechanisms critical to the func-
tion of the fluid-conducting meshwork revealed the
biological relevance of the up-regulated expression of
tissue factor pathway-associated genes—essential for
the anticoagulation properties of the intratumoral, extra-
cellular matrix-rich extravascular fluid-conducting path-
way. Gene profiling, protein detection, and immunohisto-
chemistry validation demonstrated up-regulation of tissue
factor (TF), TF pathway inhibitor 1 (TFPI-1), and TFPI-2—
critical genes that initiate and regulate the coagulation
pathways—in aggressive, as opposed to poorly aggres-
sive, melanoma. It was found that TFPI-2 contributes to
vasculogenic mimicry and endothelial transdifferentiation
by melanoma cells, whereas TFPI-1 has anticoagulant
functions for perfusion of fluid-conduction meshworks
formed by TF-expressing melanoma cells. Additional
studies have focused on the signal transduction path-
ways that regulate blood vessel formation and stabiliza-
tion during vasculogenesis and angiogenesis, address-
ing critical signaling events that regulate melanoma
vasculogenic mimicry and their endothelia-like pheno-
type.38–40 It was demonstrated that VE-cadherin and
EphA2 were co-localized in cell-cell junctions and VE-
cadherin can regulate the expression of EphA2 at the cell
membrane by mediating its ability to become phosphor-
ylated through interactions with its membrane-bound li-
gand, ephrin-A1. These studies illuminate a novel signal-
ing pathway that could be potentially exploited for
therapeutic intervention. Additional investigation uncov-
ered the role of phosphoinositide 3-kinase (PI3K) as a
critical regulator of vasculogenic mimicry, specifically af-
fecting membrane type-1 MMP (MT1-MMP) and MMP-2
activity. Both MMPs are essential for the process of vas-
culogenic network formation by aggressive melanoma
tumor cells, and the downstream effect on the cleavage
of laminin 52 chain into the 2 and 2x promigratory
fragments.38,39 Furthermore, these results showed that
blocking PI3K resulted in abrogation of vasculogenic
mimicry. Most recent studies have identified focal adhe-
sion kinase (FAK)-mediated signal transduction path-
ways to promote not only the aggressive phenotype but
also vasculogenic mimicry of melanoma cells as well.40
In addition, expression of a negative regulator of FAK
signaling, the FAK-related non-kinase in aggressive mel-
anoma cells, resulted in an inhibition of melanoma vas-
Figure 5. Endothelial progenitor cells. Schematic representation of postnatal
vasculogenesis. The term “EPC” encompasses a group of cells existing in a
variety of stages ranging from common hemangioblasts to fully differentiated
ECs. Although their putative precursors and the exact differentiation lineage
of EPCs remain to be determined, to date it is widely accepted that early EPCs
(localized in the bone marrow or immediately after migration into the
circulation) are AC133/CD34/VEGFR-2 cells, whereas circulating EPCs
are positive for CD34 and VEGFR-2, lose AC133, and begin to express cell
surface markers typical of mature ECs such as CD31, VE-cadherin, and von
Willebrand Factor (vWF).
Figure 6. Vasculogenic mimicry. This diagram represents the current inter-
pretation of data generated from several studies involving the use of tracers
and perfusion analyses of mice containing aggressive melanoma cells
(green) during tumor development. The endothelial-lined vasculature is
closely apposed to the tumor cell-formed fluid conducting meshwork, and
hypothetically, it is presumed that as the tumor remodels, the vasculature
becomes leaky, resulting in the extravascular conduction of plasma. There is
also evidence of a physiological connection between the endothelial-lined
vasculature and the extravascular melanoma meshwork.
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culogenic mimicry concomitant with a decrease in mela-
noma cell invasion and migration. This biological effect
was mediated in part through an extracellular signal-
regulated kinase 1/2 signaling pathway that resulted in a
down-regulation of urokinase and MMP-2/MT1-MMP ac-
tivity.40 These results suggest that FAK may serve as a
new target for therapeutic intervention in treating aggres-
sive melanomas with capabilities for vasculogenic
mimicry.
Antivascular Therapy of Cancer
It has been over 30 years since Judah Folkman hypoth-
esized that tumor growth is angiogenesis dependent.41
Subsequent research has led to the identification of
several regulators of angiogenesis, some of which rep-
resent therapeutic targets. However, although antivas-
cular agents are often highly active in preclinical stud-
ies, recent clinical trials including these agents have
been both encouraging and disappointing. Because of
the predominant role of capillary sprouting and its main
molecular mediator VEGF in tumor vascularization, in-
hibition of VEGF seems to be necessary but is probably
insufficient to halt tumor progression permanently in
many cancer types. Due to the existence of multiple
vascularization mechanisms and angiogenic signaling
pathways, inhibition of just a single pathway will pre-
sumably trigger alternative vascularization mecha-
nisms and additional growth factor pathways. Conse-
quently, application of antivascular therapy in cancer
patients requires the identification of the individual vas-
cularization profile and the molecular machinery be-
hind the vascularization process and, furthermore, the
individualization of antivascular therapy to realize any
potential benefits.42,43 In the second part of this re-
view, we will briefly summarize the antivascular thera-
pies that are currently being tested in the clinic. Sub-
sequently, we will give an overview of how these
classes of agents can be incorporated in the current
multimodality of anticancer strategies. Finally, we will
discuss potential novel approaches that enforce tumor
regression by exploiting the emerging basic knowl-
edge of tumor vascularization.
Antivascular Strategies in Cancer Therapy:
Current Status of the Clinical Development
Any classification of antivascular strategies is difficult,
with overlap in several features. However, the main
categories of these approaches that have been devel-
oped are angiosuppressive (anti-angiogenic agents)
and vascular-targeting therapies (vascular-disrupting
agents).44 Although metronomic chemotherapy (MCT)
uses conventional cytotoxic drugs, the main targets of
this strategy are the tumor ECs. This is the reason that
Browder et al45 coined the term “anti-angiogenic che-
motherapy” to describe this treatment and why MCT is
discussed here.
It is beyond the scope of this review to discuss all
drugs that affect tumor capillaries. Therefore, we concen-
trate here on the agents that are at a more advanced
stage of clinical development.
Angiosuppressive Therapy (Antiangiogenic
Agents)
This approach is motivated by the fact that neoangiogen-
esis in cancer requires the induction of EC proliferation
by specific or nonspecific mitogens. These agents target
the production of endothelial mitogens, the mitogens
themselves, their endothelial receptors, the associated
signaling pathways, the endothelial integrins and the
MMPs46 (Table 1). Consequently, it is most probable that
angiosuppressive therapy can only be applied when can-
cer vascularization involves EC sprouting and/or postna-
tal vasculogenesis (Table 2).
Despite the promising preclinical results with these
agents, in the early clinical trials positive responses in
patients were rarely seen. The clinical breakthrough for
angiosuppressive therapy came from a phase III trial
demonstrating a significantly prolonged survival when
bevacizumab, an anti-VEGF antibody, was used with
chemotherapy in metastatic colorectal cancer patients.47
Based on these results, bevacizumab became the first
antiangiogenic agent to be approved by the United
States Food and Drug Administration (FDA) for cancer
treatment. In subsequent phase III trials, bevacizumab in
combination with standard chemotherapy improved over-
all survival in lung cancer patients and progression-free
survival in breast cancer patients.42 In addition, it has
been reported to be active in patients with metastatic
renal-cell cancer as monotherapy (benefit in progression-
free survival but not in overall survival).48
Further clinical success was obtained recently with
broad-spectrum multitargeted agents that target VEGF
receptors and other tyrosine kinases present in endothe-
lial and cancer cells (Table 1). Phase III trials have dem-
onstrated the efficacy of SU11248/sunitinib [targeting
VEGFR-1, -2; platelet-derived growth factor receptor
(PDGFR), FLT3, and c-Kit] and BAY-43-9006/sorafenib
(targeting VEGFR-2, -3; PDGFR, RET, c-Kit, and Raf) in
the treatment of patients with renal cancer.42 Based on
these results, sunitinib and sorafenib are now approved
by the FDA as monotherapies for kidney cancer. Prom-
ising results have also been found with the combination
of ZD6474 [targeting VEGFR2, epidermal growth factor
receptor (EGFR), and RET] and chemotherapy in non-
small cell lung cancer patients. Interestingly, replacing
bevacizumab with similar tyrosine kinase (TK) inhibitors,
such as PTK787/ZK 222584/vatalanib (targeting
VEGFR-1, -2, -3; PDGFR-, and c-Kit), in the combined
regimen did not result in similar efficacy in chemothera-
py-naive or previously treated colorectal cancer pa-
tients.49 However, the clinical success of bevacizumab,
sunitinib, and sorafenib as novel medicines for the treat-
ment of cancer patients has confirmed the relevance of
angiogenesis research and has stimulated the search for
novel and more effective antiangiogenic approaches. Ac-
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cordingly, various angiosuppressive strategies are being
actively investigated, most of which are registered with
the clinical trials database of the National Cancer Institute
(http://www.nci.nih.gov/clinicaltrials).
Vascular Targeting Therapy (Vascular Disrupting
Agents; VDAs)
Vascular targeting therapy (including anti-EC antibod-
ies and ligand based and small molecule VDAs; Table
1) recognizes the fact that clinical diagnosis of cancer
frequently occurs when the tumor tissue has already
established its vasculature.44,46 This strategy relies on
ability of VDAs to distinguish the ECs of tumor capil-
laries from normal ones based on their different phe-
notype, increased proliferative potential and perme-
ability, and inherent dependence on the tubulin
cytoskeleton. VDAs cause selective and rapid shut-
down of the established tumor capillaries, resulting in
extensive cancer cell death in the central areas of
tumors, although they leave the perfusion in peripheral
tumor regions relatively intact.44,50 It is evident from
Table 1. Examples of Antivascular Agents in Clinical Development
Agent Target/mechanism of action Phase
Angiosuppressive and anti-HIF-1 agents
Anti-VEGF agents
Bevacizumab mAb against VEGF-A III; FDA-approved in
colorectal cancer
VEGF-trap VEGF-A, PlGF, VEGF-B binding I
VEGF-AS VEGF-A, VEGF-C, VEGF-D I
VEGFR and other TK receptor targeting agents
IMC-1C11 mAb against VEGFR2 I
ZD6474 VEGFR-2, EGFR, RET I/II
PTK787/ZK222584 (vatalanib) VEGFR-1, -2, -3; PDGFR-, c-Kit II/III
BAY 43–9006 (sorafenib) VEGFR-2, -3; PDGFR, RET, c-Kit, Raf III; FDA-approved in
renal cancer
SU11248 (sunitinib) VEGFR-1, -2; PDGFR, FLT3, c-Kit III; FDA-approved in
renal cancer
AG-013736 VEGFR-1, -2, -3; PDGFR-, c-Kit I/II
Angiozyme VEGFR-1 mRNA-destroying ribozyme I/II
Integrin signaling
EMD 121974 (Cilengitide) Mimicking the RGD ligand recognition peptidic
domain common to v integrin ligands
I/II
MEDI-522 (Vitaxin) mAb against v3 I/II
Miscellaneous
Thalidomide Multiple inhibitory effect on bFGF, VEGF, and
TNF--induced EC sprouting
I/II
AE-941 Inhibitor of MMP-2, -9, -12, and VEGFR-2 II/III
Marimastat MMP2/9 III
Bay-12-9566 MMP2/9 III
AG3340 MMP2/9 III
Endostatin Integrin 51 II/III
ABT-627 Endothelin receptor II/III
Nonselective inhibitors of HIF-1
Topotecan and other camptothecin analogues,
DX-2-1, GL331
Topoisomerase I/II Preclinical; phase I
2-Methoxyestradiol Microtubules I
YC-1 Soluble guanyl cyclase Preclinical
PX-478 Translation/deubiquitination Preclinical
17-AAG, geldanamycin, radicicol, KF58333 HSP-90 Preclinical
VDAs
Ligand-directed VDAs
L19 single chain Fv ED-B domain of fibronectin Preclinical
mAb against endoglin linked to ricin-A Endoglin Preclinical
Anti-VCAM-1 AB linked to coagulation inducing
protein TF
VCAM-1 Preclinical
Anti-TES-23 linked to neocarzinostatin CD44-related EC marker Preclinical
Naked AB against phosphatidylserine Phosphatidylserine Preclinical
v3 targeting ligand delivering EC apoptosis
inducing ATP-Raf
Targeted ATP-Raf gene Preclinical
Small molecule VDAs
CA4-prodrug; AVE8062 and Oxi4503 (synthetic
analogues of combretastatin)
Actin polymerization, filament stabilization via
Rho signaling pathway
I/II
ZD6126 Inhibition of EC microtubule polymerization I
ABT-751 -Tubulin I
DMXAA (analogue of flavone acetic acid) TNF- release, induction of nuclear factor- I/II
mAb, monoclonal antibody; PlGF, placenta growth factor; bFGF, basic fibroblast growth factor; 17-AAG, 17-N-allylamino-17-demethoxygeldan-
amycin; VCAM-1, vascular cell adhesion molecule-1; CA4, combrestatin-A4.
Alternative Vascularization Mechanisms in Cancer 9
AJP January 2007, Vol. 170, No. 1
the mechanism of VDAs that the effects of these drugs
do not depend on the type of vascularization occurring
in a given cancer. Based on promising preclinical de-
velopments, several VDAs have entered clinical
development.51
MCT and Its Antivascular Effects
Among the different antivascular strategies, MCT merits
particular mention. MCT refers to the close, even daily,
administration of chemotherapeutic drugs in doses below
the maximum tolerated dose, over prolonged periods,
and with no extended drug-free breaks. Phase II trials of
MCT, sometimes applied in combination with antiangio-
genic drugs, have yielded promising results in adult pa-
tients with advanced cancer.52,53 Furthermore, pediatric
oncologists successfully use a metronomic-like modality
of chemotherapies called “maintenance chemotherapy”
to treat various pediatric malignancies such as acute
lymphoblastic leukemia, neuroblastoma, or Wilms’ tumor;
however, the anti-angiogenic background of mainte-
nance chemotherapy is poorly described.54
Although cytotoxic effects of MCT in the tumor paren-
chyma could still contribute to the observed efficacy of
metronomic regimens, preclinical studies suggest that
the primary targets of MCT are the tumoral ECs. Low-
dose chemotherapy affects tumor capillaries directly
(growth arrest and apoptosis of activated ECs) but also
induces the production of an angiogenesis inhibitor
thrombospondin-1 and suppresses the mobilization of
EPCs.52
As mentioned above, several phase I and II studies
were performed involving low, continuous doses of cyto-
toxic drugs, with encouraging results.53 However, the
clinical benefits of MCT remain to be validated in ran-
domized prospective phase III trials. There is also a need
for surrogate markers to help define the optimal dose of
this approach. Circulating ECs55 and EPCs56 have been
used successfully as markers in preclinical and early
clinical studies but have not yet been validated clinically.
Further challenges are the definition of valid clinical end-
points, the confirmation of long-term safety of MCT, and
the identification of suitable antiangiogenic agents and
VDAs to be combined with MCT. Finally, it will be impor-
tant to determine the types of vascularization that might
be the most responsive to this therapy. MCT is probably
more effective in EC sprouting, postnatal vasculogenesis,
IMG, and vasculogenic mimicry (Table 2). However, de-
tailed clinicopathologic analysis is needed to confirm this
hypothesis.
Considerations for Combination Treatment
Strategies
Because antivascular agents and traditional anticancer
strategies have distinctive target cells and mechanisms
of action, it should be possible to achieve an increase in
therapeutic efficacy with little or no increase in toxicity.
In fact, although some antivascular agents have dem-
onstrated activity as monotherapies, most human trials
to date indicate that they are most effective when
combined with conventional antitumor strategies, es-
pecially chemotherapy.42,43
Combination of Angiosuppressive and Chemo-
and/or Radiation Therapy
Angiosuppressive therapy reduces cancer growth by
suspending the blood supply, resulting in hypoxia. Be-
cause hypoxia itself is a major cause of ineffective
chemo-irradiation therapy,57 one would expect that a
further decrease in intratumoral oxygen levels would de-
teriorate the efficacy of a cytotoxic regime, but experi-
mental and clinical data do not support this scenario. In
Table 2. Theoretical Strategy of Antivascular Therapy of Cancer According to the Stage of Tumor Progression and to the
Mechanisms of Vascularization
Type of vascularization
Individual cancer cells
in host tissue
Microscopic tumor
pre-angiogenic phase
Microscopic tumor
angiogenic phase Macroscopic tumor
Sprouting Antiangiogenic agents;
metronomic
chemotherapy
Antiangiogenic agents;
metronomic
chemotherapy
Antiangiogenic agents;
metronomic
chemotherapy
Antiangiogenic agents;
“vascular targeting”
therapy; metronomic
chemotherapy
Intussusceptive
microvascular growth
N.A. N.A. Vascular targeting
therapy; metronomic
chemotherapy
Vascular targeting
therapy; metronomic
chemotherapy
Vessel co-option N.A. N.A. Vascular targeting
therapy
Vascular targeting
therapy
Glomeruloid angiogenesis N.A. N.A. Vascular targeting
therapy
Vascular targeting
therapy
Vasculogenic mimicry N.A. N.A. Vascular targeting
therapy; metronomic
chemotherapy
Vascular targeting
therapy; metronomic
chemotherapy
Postnatal vasculogenesis
(endothelial progenitors)
N.A. N.A. Antiangiogenic agents;
vascular targeting
therapy; metronomic
chemotherapy
Antiangiogenic agents;
vascular targeting
therapy; metronomic
chemotherapy
N.A., not applicable.
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several preclinical models, a combination of cytotoxic
drugs (taxanes, cisplatin, or 5-fluorouracil) with angio-
genesis inhibitors (TNP470, endostatin, SU11248) pro-
duced at least additive but in certain cases synergistic
antitumoral effects.46 Thalidomide, a still ill-defined an-
giogenesis inhibitor, has also been shown successful
preclinically in combination with standard anticancer re-
gimes in solid tumors.58 In addition to experimental data,
there are now clinical examples of the improved efficacy
of chemotherapy in combination with an angiosuppres-
sive agent. As mentioned above, bevacizumab in com-
bination with chemotherapy improved overall survival in
colorectal and lung cancer patients and progression-free
survival in breast cancer patients (see review42). In ad-
dition, the combination of bevacizumab and chemother-
apy was found to be active in pancreatic59 and ovarian60
cancer patients.
There are several explanations for the improved effi-
cacy. An obvious effect of angiogenesis inhibitors is the
decrease in interstitial pressure in cancer tissue improv-
ing the delivery of cytotoxic agents. Furthermore, a hy-
pothesis called “normalization of tumor vasculature” was
put forth by Jain and colleagues recently to explain the
clinical effects of antiangiogenic agents.42 According to
this theory, tumor vasculature is structurally insufficient to
provide maximal blood supply for cancer cells as a result
of capillary leakiness and tortuosity. Because the key
regulator cytokine family of tumoral vessels is the VEGF/
VEGFR system, targeting it could potentially help in the
“normalization” of tumor vasculature and in the improve-
ment of the delivery of chemotherapeutic agents.42 Ac-
cordingly, recent experimental data indicate that anti-
VEGF therapy induces rapid alterations in tumor
vasculature. Within a few hours, EC proliferation is halted,
luminal stability vanishes, and circulation ceases in tumor
capillaries. Some ECs undergo apoptosis and disappear.
Remaining capillaries lack endothelial fenestrations and
have reduced VEGFR-2 and VEGFR-3 expression.61
Thus, inhibition of VEGF signaling devastates some tumor
capillaries and transforms others into a more normal
phenotype.42
Further mechanisms for the additional benefits experi-
enced for combined chemo- and angiosuppressive ther-
apy might be the direct killing of proliferating ECs and/or
the inhibition of the mobilization/viability of EPCs by cy-
totoxic drugs. Results of preclinical studies support this
hypothesis. On the other hand, VEGF inhibition might
have direct cytotoxic effects on tumor cells that aber-
rantly express VEGF receptors and depend to some ex-
tent on VEGF for their survival. Finally, it has also been
suggested recently that antiangiogenic agents prevent
rapid cancer cell repopulation during the break periods
between courses of chemotherapy (see review43).
Experimental studies indicate that antiangiogenic ther-
apy in combination with irradiation is an encouraging
concept for the improvement of the radiation response of
tumors.62 In addition, recent discoveries show that the
EC layer of the tumor vessels is one key target of radio-
therapy.63 In fact, the antivascular effect of radiotherapy
predicts its anti-cancer effect.64 Thus far, although early
phase human trials have also yielded promising results,
there are no large phase III trials known in which such
combinations were successfully applied. Nevertheless,
the discovery of the “normalization window” of angiosup-
pressive agents when combined with radiotherapy in
preclinical models65 suggests that it would be as difficult
to design a successful combination strategy with radia-
tion as with chemotherapy.
In this normalization window (the time period during
which the vasculature normalizes and hypoxia de-
creases), the antiangiogenic drugs improve the efficacy
of chemoradiotherapy.42 Although these studies were
performed in experimental tumor systems, one may ex-
pect a similar effect on the human tumor vasculature and
oxygenation. However, intratumoral hypoxia, responsible
for chemo- and radiotherapy resistance and triggering
molecular pathways that promote cancer progression, is
due not only to the inefficient blood supply by the abnor-
mal tumor vessels but to the systemic anemia of the host
as well.66 Unfortunately, although the oxygen tension of
experimental tumors tends to rise with increasing Hb
levels67 and treatment with recombinant human erythro-
poietin (rHuEpo) significantly reduces the risk for red
blood cell transfusions in cancer patients, correction of
anemia with rHuEpo does not necessarily improve sur-
vival of cancer patients.66 The issue of Epo/EpoR co-
expression in tumor cells and EpoR expression in ECs is
critical in this perspective. The expression of EpoR in
tumor cells has raised the possibility that exogenous
rHuEPO may directly influence cancer cell proliferation,
apoptosis, or sensitivity to chemoradiation therapy. In
addition, the EpoR expression in ECs has suggested
potential effects of Epo on the tumor capillaries, such as
the stimulation of angiogenesis.68 However, as it has
been suggested by experimental studies, the overall di-
rect effect of Epo-EpoR signaling on tumor progression and
therapy is not a straightforward one. For instance, rHuEpo
administration has recently been shown to be associated
with decreased intratumoral VEGF expression, remodeling
of tumor capillaries, and increased chemosensitivity to 5-flu-
orouracil treatment of human tumor xenografts.69 In a pre-
clinical myeloma model, rHuEpo induced tumor regression
and antitumor immune responses.70 In addition, human
kidney carcinoma and myelomonocytic leukemia cell lines
treated with rHuEpo exhibited an increase in apoptosis in
response to chemotherapy.71 Overall, these findings war-
rant additional experimental and clinical research of rHuEpo
to clarify further the risks of its use as well as optimize its
known or potential benefits.
Combination of VDAs and Chemo- and/or
Radiation Therapy
VDAs work best in the poorly perfused hypoxic central
tumor areas, leaving a viable rim of well-perfused cancer
tissue at the periphery, which rapidly regrows.50 Conse-
quently, responses of tumors to VDAs given as single
agents have been poor; however, combination therapy
with chemoradiotherapy, which targets cancer cells at
the tumor periphery, has produced promising responses
in preclinical models. Nevertheless, the timing and se-
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quencing of VDAs and chemo-irradiation therapies are
important in such treatments. By far the greatest en-
hancement was observed when the VDA was adminis-
tered within a few hours after chemo- and/or irradiation
therapy. Based on these experimental results, the
VDA compounds 5,6-dimethylxantlenone-4-acetic acid
(DMXAA) and combretastatin A4 phosphate (CA4P) are
being evaluated in human phase II trials in combination
with conventional anticancer therapies.51
Combination of Angiosuppressive and Vascular
Disrupting Agents
Because both angiogenesis and the integrity of the ex-
isting vasculature are critical to tumor progression and
survival, dual targeting of the tumor vasculature would
seem to have considerable promise. Preclinical results
demonstrated that this strategy could significantly enhance
therapeutic response beyond that achieved with either an-
tivascular agent alone.51 One example of this strategy is the
combination of the inhibitor of VEGFR2-associated TK
ZD6474 with the microtubulin-disrupting VDA ZD6126.72
Further combinations that are under preclinical testing in-
clude the combination of OXi-4503, CA4P, and DMXAA with
bevacizumab. Clinical testing of combined antivascular
therapy has started with the recent initiation of a phase I
human trial combining CA4P with bevacizumab.51
Theoretical Considerations for Designing
Antivascular Therapy of Cancer
From the discussion above it is clear that the combination
of either angiosuppressive or the vascular disrupting
therapies with conventional chemoradiotherapy of can-
cer is highly problematic and must be carefully designed
in cases where the sequence of the multiple types of
agents might be critical. The molecular machinery behind
the vascularization process and type of tumor vascular-
ization are further issues that have to be taken into ac-
count. Thus, an efficient antivascular cancer therapy
could be designed based on the identification of the
molecular targets of the angiogenic geno-/phenotype
(molecular pathway-based approach) or on the vascular-
ization mechanism (vascular mechanism-based ap-
proach). However, it is most probable that the two ap-
proaches would have to be combined. We propose
below a rationale for the design of antivascular strategies
with the aim that such consideration may help to improve
the clinical efficacy of these novel therapies.
Molecular Pathway-Based Antivascular Therapy
of Cancer
Because of its pivotal role in neovascularization, the
VEGF/VEGFR axis has been a major target of basic and
clinical research. It is, therefore, not surprising that most
of the antivascular strategies currently in clinical devel-
opment focus on inhibition of VEGF signaling.46,73 How-
ever, the development of the angiogenic phenotype of
cancer is characterized by several interconnected path-
ways. One of the major triggers of this phenotype is tissue
hypoxia, which is responsible for the activation of gene
expression of angiogenic cytokines through up-regula-
tion of the transcription factor hypoxia inducible factor-1
(HIF1-). Nevertheless, HIF-1 may already be active in
particular cancers due to hyperactive growth factor sig-
naling or genetic alteration of the HIF1 gene itself or its
regulators [ie, von Hippel-Lindau (VHL) and p53].74 Be-
cause HIF-1 plays such a central role in triggering nu-
merous pathways responsible for cancer progression,
disruption of the HIF-1-mediated pathways is expected to
cause cancer cell death due to a combination of meta-
bolic dysregulation and reduced microvessel growth.
The aim of anti-HIF-1 therapy (used as an antivascular
modality) therefore might be to cause the angiogenic
phenotype of cancer to revert to a less angiogenic one,
thereby preventing the production of the major angio-
genic cytokines.75 HIF1 can be inhibited by guanyl cy-
clase or HSP90 inhibitors and even by the targeting of
topoisomerase-1, and several of such agents are in clin-
ical trials (Table 1). However, none of the currently avail-
able inhibitors seems to disrupt the HIF-1 pathway as
their exclusive target.75 If the additional targets of non-
selective HIF-1 inhibitors are also involved in cancer pro-
gression, these agents could be therapeutically benefi-
cial, but inhibition of the pathways involved in normal
cellular homeostasis could result in an unacceptable tox-
icity profile. Therefore, the design of more specific HIF-1
targeting agents is the focus of current research efforts.
However, it is also important to note that HIF-1 targeting
alone may not be enough to halt angiogenesis and tumor
progression, as HIF-independent pathways may bypass
or overcome HIF inhibition. Consequently, a combination
of anti-HIF agents with conventional anticancer modali-
ties or other molecular-targeted drugs may be required.
VEGF expression is not only associated with hypoxia or
VHL mutations but also is influenced by a broad spec-
trum of onco- and tumor suppressor genes. A growing
body of evidence suggests that inactivation of tumor
suppressor genes such as p53 and PTEN and activation
of oncogenes such as Ras, c-Src, EGFR, human epider-
mal growth factor receptor 2 (HER-2), FBJ murine osteo-
sarcoma viral oncogene homolog (FOS), neurotrophic
receptor tyrosine kinase B (trkB), V-p3K, and Bcl-2 are
connected to the up-regulation of VEGF. Consequently,
molecular targeting of these regulators is also a potential
strategy for indirectly modulating the VEGF/VEGFR axis.73
For example, based on the results of recent clinical trials,
cetuximab (a monoclonal antibody that binds to EGFR with
high specificity) induces a significant decrease in circulat-
ing VEGF levels in colon cancer patients,76 or likewise,
imatinib mesylate (a specific inhibitor of Bcr/Abl protein TK
activity) reduces VEGF plasma concentration77 and bone
marrow microvessel densities78 in patients with chronic my-
eloid leukemia. However, preclinical and early phase clini-
cal data demonstrate that the addition of anti-VEGF therapy
to anti-EGFR therapies generates further beneficial effects
on angiogenesis inhibition and tumor reduction.42 This sug-
gests that inhibiting upstream signaling of VEGF does not
necessarily provide the same benefit as the direct targeting
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of it and, more importantly, that the dual targeting of cancer
and endothelial cells might become a successful practice in
clinical oncology.
Mechanism-Based Antivascular Therapy of
Cancer
A proposal for the application of antivascular therapies
according to the alternative vascularization mechanisms
in cancer is summarized in Table 2. Probably the most
important aspect of mechanism-based antivascular ther-
apy is its strict dependence on the stage of tumor pro-
gression. Interestingly, antivascular therapy may have an
effect at the very early stages of tumor growth. This idea
was put forward by Li et al,79 who analyzed the earliest
events that take place during the onset of tumor neovas-
cularization and found that individual tumor cells exhib-
ited a chemotaxis-like growth pattern toward the host
vasculature. When the tumor cell population reached
approximately 60 to 80 cells, clear evidence of perivas-
cular tumor cell migration (ie, vessel co-option), and host
vessel dilation was observed. Moreover, in a mouse
model of glomeruloid angiogenesis, our group found that
even single tumor cells can induce radical changes in the
host tissue vasculature24 (Figure 4). These observations
are important in two ways. First, they suggest that anti-
invasive agents (which are not yet available clinically)
may have a therapeutic effect on the interaction between
cancer and endothelial cells and, consequently, on the
processes of vessel co-option and glomeruloid angio-
genesis. Second, the finding that single tumor cells can
induce increased capillary permeability/tortuosity high-
lights the need for application of angiosuppressive/anti-
angiogenic therapy at the very early stages of cancer
progression. These considerations may be true for the
next step of tumorigenesis (pre-angiogenic phase) as
well.
After the onset of “angiogenic switch,” elevated serum
levels of angiogenic growth factors in cancer patients
may activate and mobilize EPCs to support local mi-
crovessel growth.26 If we accept this assumption, then, in
addition to angiogenesis inhibitors and metronomic che-
motherapy,52 ligand-based, EPC-specific VDAs may also
be useful in eliminating circulating EPCs throughout the
further stages of tumor progression (Table 2). Further-
more, because IMG can be effective only in tumor cap-
illary networks already built by other vascularization
mechanisms (mainly sprouting and vessel co-option),
steps should be taken to impede the additional increase
in the density of the tumor tissue capillary bed following
the angiogenic switch. This could be achieved by the use
of VDAs and/or “metronomic chemotherapy,” which both
target the cytoskeleton of ECs responsible for the remod-
eling of capillary walls.
Because ischemic milieu is what forces aggressive
tumor cells to express endothelial genes and form vas-
cular channels,33,80 the initiation of this mechanism is
most likely simultaneous with the angiogenic switch.
Therefore, when vasculogenic mimicry plays a role in the
nutrient supply in cancer, besides the use of ligand-
based VDAs against cancer cells with endothelial phe-
notype, targeting those pathways responsible for the de-
velopment of this mechanism such as Eph2A, PI3K, or
FAK seems to be an appropriate strategy. On the other
hand, metronomic scheduling of chemotherapy52 may
also effectively target cancer cells with vasculogenic
geno/phenotype when both physiological angiogenesis
inhibitors and angiosuppressive drugs are unable to
modify this vascularization mechanism.80
The next stage of malignant progression is when
tumor tissue reaches macroscopic size detectable by
simple or sophisticated imaging techniques. As we
know, for cancer survival “the edge is the future and
the center is history,”81 because active tumor vascu-
larization processes, resulting in vascular networks
built by defective new capillaries, occur mainly, though
not exclusively, at the tumor periphery. Consequently,
at this stage the main target of antivascular therapies is
the invading front of the cancer tissue. However, since
in addition to causing chemo- and radiotherapy resis-
tance, reduction of vascularity in the center of tumors
can lead to the appearance of more aggressive/highly
metastatic hypoxia-resistant cancer cells and to the
induction of vasculogenic mimicry, when designing
antivascular strategies central tumor areas cannot be
neglected. We should emphasize, therefore, that in the
case of clinically detectable tumors the whole range of
antivascular weapons should be used theoretically.
Although antiangiogenic agents targeting proliferating
ECs could possibly be the key drugs at the tumor
boundary, established tumor vasculature might well be
attacked by VDAs and/or metronomic chemotherapy in
the central tumor areas. Altogether, it seems feasible
that antivascular therapy in tumors can only be suc-
cessful if the entire vascular network and all of the
possible vascularization mechanisms are targeted
and, furthermore, if the phenotypic analysis of tumor
capillaries/vascular channels is adequately performed.
Conclusion
Although tumors, as other tissues, require a vessel net-
work supplying them with blood, tumor vasculature is not
necessarily derived by EC proliferation and sprouting of
new capillaries. In addition to alternative vascularization
mechanisms, the novel antivascular strategies must be
harmonized with the stage of tumor progression and with
the molecular mechanism responsible for the angiogenic
phenotype. A further challenge is to combine antivascu-
lar strategies with the existing therapeutic regimes in at
least an additive manner. We have provided here pro-
posals for a rational application of antivascular agents
with the notion that these therapies have to be individually
tailored in a given cancer type. Better understanding of
the different vascularization mechanisms of the various
cancer types will certainly help to fine-tune these novel
anti-cancer strategies.
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